Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer

NCT05869097 · clinicaltrials.gov ↗

COMPLETED

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Adenocarcinoma

Interventions

DRUG: Trifluridine/Tipiracil
DRUG: Bevacizumab

Sponsor

Hunan Cancer Hospital